We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kronos (KRO) Scales New 52-Week High on Bright Prospects
Read MoreHide Full Article
Shares of chemicals maker, Kronos Worldwide, Inc. (KRO - Free Report) , scaled a fresh 52-week high of $20.64 yesterday, before pulling back to eventually close the day at $20.47.
Kronos has a market cap of roughly $2.4 billion. Average volume of shares traded in the last three months is around 498.7k.
Kronos has significantly outperformed the Zacks categorized Chemicals-Diversified industry over the last one year, partly reflecting its forecast-topping earnings performance. The company’s shares have returned a whopping 249.9% over this period, compared with roughly 19.9% gains recorded by the industry.
Driving Factors
Kronos swung to a profit of $36.8 million or 32 cents per share in first-quarter 2017 from a loss of $3.8 million or 3 cents per share a year ago. Earnings per share topped the Zacks Consensus Estimate of 22 cents.
Kronos also has an impressive earnings surprise history, outpacing the Zacks Consensus Estimate in three of the trailing four quarters. The company delivered a positive average earnings surprise of around 64.1% in the said time frame.
Kronos provided an upbeat guidance for 2017. The company expects production volumes to be higher in 2017 on a year-over-year basis as production rates this year will be favorably impacted by the implementation of certain productivity-enhancing projects at some facilities. It also sees healthy demand for its titanium dioxide (TiO2) products across some of its primary markets.
Kronos also expects income from operations in 2017 to be higher on a year-over-year basis, due to an expected increase in average selling prices and the favorable impact of anticipated higher production volumes in 2017.
Sherwin-Williams has an expected long-term earnings growth rate of 11.4%.
Ternium S.A. has an expected long-term earnings growth rate of 18.4%.
Hitachi Chemical has an expected long-term earnings growth rate of 5%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kronos (KRO) Scales New 52-Week High on Bright Prospects
Shares of chemicals maker, Kronos Worldwide, Inc. (KRO - Free Report) , scaled a fresh 52-week high of $20.64 yesterday, before pulling back to eventually close the day at $20.47.
Kronos has a market cap of roughly $2.4 billion. Average volume of shares traded in the last three months is around 498.7k.
Kronos has significantly outperformed the Zacks categorized Chemicals-Diversified industry over the last one year, partly reflecting its forecast-topping earnings performance. The company’s shares have returned a whopping 249.9% over this period, compared with roughly 19.9% gains recorded by the industry.
Driving Factors
Kronos swung to a profit of $36.8 million or 32 cents per share in first-quarter 2017 from a loss of $3.8 million or 3 cents per share a year ago. Earnings per share topped the Zacks Consensus Estimate of 22 cents.
Kronos also has an impressive earnings surprise history, outpacing the Zacks Consensus Estimate in three of the trailing four quarters. The company delivered a positive average earnings surprise of around 64.1% in the said time frame.
Kronos provided an upbeat guidance for 2017. The company expects production volumes to be higher in 2017 on a year-over-year basis as production rates this year will be favorably impacted by the implementation of certain productivity-enhancing projects at some facilities. It also sees healthy demand for its titanium dioxide (TiO2) products across some of its primary markets.
Kronos also expects income from operations in 2017 to be higher on a year-over-year basis, due to an expected increase in average selling prices and the favorable impact of anticipated higher production volumes in 2017.
Kronos Worldwide Inc Price and Consensus
Kronos Worldwide Inc Price and Consensus | Kronos Worldwide Inc Quote
Zacks Rank & Key Picks
Kronos currently carries a Zacks Rank #3 (Hold).
Some better-ranked companies in the basic materials space are The Sherwin-Williams Company (SHW - Free Report) , Ternium S.A. (TX - Free Report) and Hitachi Chemical Company, Ltd. . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
Sherwin-Williams has an expected long-term earnings growth rate of 11.4%.
Ternium S.A. has an expected long-term earnings growth rate of 18.4%.
Hitachi Chemical has an expected long-term earnings growth rate of 5%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>